Skip to main content

Advertisement

ADVERTISEMENT

Peer Review

Peer Reviewed

Original Research

Inflammatory Markers in Diabetic Foot Infection: A Meta-Analysis

December 2023
1943-2704
Wounds. 2023;35(12):425-432. doi:10.25270/wnds/082421.03

Abstract

Introduction. Diabetic foot infection is a serious and painful process for patients with diabetes, and the considerable morbidity associated with the condition warrants attention. Effective inflammatory markers may become important in the detection of diabetic foot infection. Objective. The goal of the research was to systematically assess the function of inflammatory markers in the detection of diabetic foot infection. Methods. Online databases including PubMed, SpringerLink, and Web of Science were searched. The quality of research and data was assessed using the Newcastle-Ottawa Scale. A random-effects model was used to compare changes in inflammatory markers between patients with infected diabetic foot (IDF) and patients with non-infected diabetic foot. Results. Ten studies with 785 participants were included in the systematic review. The study analyzed 3 inflammatory markers: white blood cell (WBC) count, C-reactive protein (CRP) level, and procalcitonin (PCT) level. The meta-analysis indicated that mean WBC count (standardized mean differences [SMD]: 0.51, 95% CI: 0.23, 0.79; P < .0001), mean CRP level (SMD: 1.05, 95% CI: 0.60, 1.50; P < .0001) and mean PCT level (SMD: 0.80, 95% CI: 0.36, 1.24; P < .0001) were higher in patients with IDF. The differences were statistically significant, but the funnel plots indicated the existence of publication bias. Conclusions. The meta-analysis further confirmed the significant association between inflammatory markers and diabetic foot infection. It also confirmed that WBC count, CRP level, and PCT level can be used as laboratory auxiliary indexes in the detection of diabetic foot infection, providing information for improved diagnosis and prevention.

How Do I Cite This?

Wang YT, Zhang LX, Li Y, Zhao J, Chen HL. Inflammatory markers in diabetic foot infection: a meta-analysis. Wounds. 2023;35(12):425-432. doi:10.25270/wnds/082421.03

Introduction

Diabetic foot is one of the most serious complications of diabetes, with a global prevalence of 6.3%.1 Currently, diabetic foot infection affects about 15% of patients with diabetes.2 Diabetic foot infection is clinically considered to be soft tissue or bone infection below the ankle, including paronychia, cellulitis, myositis, abscess, necrotizing fasciitis, septic arthritis, tendonitis, and osteomyelitis.3 The considerable morbidity associated with infected diabetic foot (IDF) warrants attention, and the development of preventive measures is of particular importance. These infections account for the majority of hospitalizations associated with diabetes other than non-traumatic amputation.4 The treatment process increases the economic burden on patients. Additionally, according to the clinical data, up to 28% of diabetic foot ulcers with IDF may require some type of lower extremity amputation.5 

Some studies have used inflammatory markers to detect diabetic foot infection, while others have not. Typical markers include white blood cell (WBC) count, C-reactive protein (CRP) level, and procalcitonin (PCT) level.6 Many studies of the diabetic foot include the detection of more than 1 of these inflammatory markers.7-9 In general, elevated inflammatory markers are considered a sign of infection, rising again after initial values fall, or rising over an extended period.10 However, 1 study found no significant difference in WBC count  between patients with IDF and patients with non-infected diabetic foot (NIDF).11 Another study indicated that CRP level is not a valuable marker of infection in patients with diabetic foot.12 Additionally, a pilot study with a small number of cases showed that PCT level was not significantly higher in patients with IDF, even in those who had undergone amputation.13 However, 2 studies proposed that WBC count, CRP level, and PCT level were significantly different before and after infection, which suggests that these could be used as effective inflammatory markers in the detection of diabetic foot infection.14,15

As noted previously, as of this writing no meta-analysis existed confirming the significant differences in WBC count, CRP level, and PCT level between patients with IDF and patients with NIDF. Therefore, no reliable evidence existed for the clinical use of inflammatory markers to assist in the detection of diabetic foot infection. The purpose of this study was to investigate whether WBC count, CRP level, and PCT level are helpful in detecting diabetic foot infection.

Methods

Database and literature search

PubMed, SpringerLink, and Web of Science databases were searched electronically using 3 search terms: “diabetic foot,” “infection,” and “inflammatory markers.” These search terms and their combinations with “AND” or “OR” were searched separately; searches were done separately when searching article title and abstract. Manual retrieval of relevant studies and the related data were extracted according to the standard research practice.

Study selection

The following criteria were used to select relevant studies. First, observational studies were chosen; these included prospective cohorts, retrospective cohorts, and cross-sectional surveys.16 Second, other study types were excluded; these included letters, meeting abstracts, animal experiments, biological research, non-English language studies, studies with no data, and studies that did not analyze infection and non-infection separately. Two of the authors (LXZ and JZ) reviewed the titles and abstracts and excluded literature that did not satisfy the study criteria. They evaluated the full-text versions of the remaining studies and selected studies for this meta-analysis. During the selection process, differences among reviewers and quality assessments were resolved through discussion and consensus.

Data extraction and quality assessment

Author, publication year, country, study design, study duration, patient age, male to female ratio, the proportion of patients with and without diabetic foot infection, WBC counts, CRP levels, and PCT levels were extracted. The predictive variables included the number of patients with IDF and with NIDF as well as WBC, CRP, and PCT concentrations.

The Newcastle-Ottawa Scale was used to evaluate the quality of studies and data.17 The scores were presented with concrete numerical values, and the full score was 9 points. Studies were judged based on 3 broad factors—selection, comparability, and outcome. Selection includes 4 items with a maximum value of 1 point each: representation of the exposed cohort, selection of the non-exposed cohort, certainty of exposure, and demonstration that an outcome of interest was not present at the start of the study; comparability consists of control-matched significant factors (1 point) and research controlled (1 point); and outcome consists of assessment of outcomes (1 point), follow-up long enough for outcomes to occur (1 point), and advocacy of follow-up cohorts (1 point).

Data synthesis and analysis

For continuous data, the standardized mean differences (SMD) and 95% CIs were analyzed. The present authors conducted a random-effects model to analyze statistical heterogeneity. The random-effects model also resulted in a wider range of linear relationships and more conservative accuracy estimates.18 Statistical heterogeneity was evaluated using the inconsistency statistic (I2). The I2 values ranged from 0% to 100%, with higher values indicating increasing heterogeneity.19 The funnel plot was mainly used to evaluate for publication bias. Subgroup analysis was conducted by prospective and retrospective analysis. All statistical analyses were carried out using Stata15.0 (StataCorp LLC).

Results

Identification of eligible studies

A total of 1937 potential articles met the search criteria. The study authors (LXZ and JZ) removed 1305 duplicate articles. After an initial screening of all titles and abstracts, 454 articles were excluded, and the present authors assessed 178 articles for eligibility. The final analysis included 10 studies.7-9,12,20-25 A flow diagram of the selection process is shown in Figure 1.

Characteristics of the included studies

A total of 785 participants were identified using the search strategy noted previously. The number of participants per study ranged from 12 to 89. Participant age ranged from 28 years to 80 years. Among them, 490 participants were patients with IDF, and 295 participants were patients with NIDF. The main study characteristics included author, publication year, country, study design, number of patients, IDF/NIDF status, infection rate, age, sex (male or female), detection methods, and quality score. These characteristics are summarized in Table 1. Data including WBC count, CRP level, and PCT level were presented as mean ± SD and are summarized in Table 2. The mean quality score of the Newcastle-Ottawa Scale was 7.0 (out of a possible 9 points).

Meta-analysis of WBC count

The forest plot shows the mean WBC count of retrospective studies (SMD: 0.44, 95% CI, −0.28, 1.17) and prospective studies (SMD: 0.54, 95% CI, 0.21, 0.88) (Figure 2A). Overall, mean WBC count (SMD: 0.51, 95% CI, 0.23, 0.79) was higher in patients with IDF. The forest plot, funnel plot, and sensitivity diagram of WBC count are shown in Figure 2.  Heterogeneity was confirmed in the WBC-related data (overall I2 = 61.0%). The statistical test of the combined effect of WBC count was 3.57 (P <.0001), which was significant. The funnel plot shows that the WBC values before and after infection were not symmetrical to the meta-analysis, indicating the possibility of publication bias. Judging from the sensitivity analysis, the point estimates of all the results fell within 95% CI of the combined effect. All these results show that the overall stability of this study is good. 

Meta-analysis of CRP level

The forest plot shows the mean CRP level of the retrospective studies (SMD: 0.49, 95% CI, 0.18, 0.80) and the prospective studies (SMD: 1.34, 95% CI, 0.77, 1.91) (Figure 3A). Overall, mean CRP level (SMD: 1.05, 95% CI, 0.60, 1.50) was higher in patients with IDF. The forest plot, funnel plot, and sensitivity diagram of CRP level are shown in Figure 3. Heterogeneity was high (overall I2 = 86.1%). The statistical test of the combined effect of CRP level was 4.56 (P <.0001), which was significant. The funnel plot shows that CRP levels before and after infection were not symmetrical to the meta-analysis, indicating the possibility of publication bias. The remaining studies were reanalyzed after excluding the independent studies, and the point estimates of all the results fell within 95% CI of the combined effect. All these results showed that the overall stability of this study was good. 

Meta-analysis of PCT level

The forest plot shows the mean PCT level of retrospective studies (SMD: 0.95, 95% CI, 0.35, 1.54) and prospective studies (SMD: 0.78, 95% CI, 0.27, 1.28) (Figure 4A). Overall, the mean PCT level (SMD: 0.80, 95% CI, 0.36, 1.24) was higher in patients with IDF. The forest plot, funnel plot, and sensitivity diagram of PCT level are shown in Figure 4. Heterogeneity was high (overall I2 = 81.1%). The statistical test of the combined effect of PCT was 3.60 (P <.0001), which was significant. The funnel plot shows that PCT level before and after infection was not symmetrical to the meta-analysis, indicating the possibility of publication bias. After the sensitivity analysis, the authors found that the inclusion of the fourth study had a significant effect on the stability of the whole PCT value; thus, the meta-analysis of PCT level is unstable.

Discussion

The study reported herein found significant differences in WBC count, CRP level, and PCT level between patients with IDF and patients with NIDF, with mean WBC count (SMD: 0.51, 95% CI, 0.23, 0.79), CRP level (SMD: 1.05, 95% CI, 0.60, 1.50), and PCT level (SMD: 0.80, 95% CI, 0.36, 1.24) higher in patients with IDF (P <.0001 for all). A meta-analysis of risk factors for amputation showed that increased WBC counts (SMD: 0.8, 95% CI, 0.449, 1.146) and elevated CRP levels (SMD: 0.8, 95% CI, 0.561, 1.035) were identified as risk factors for amputation.26 However, the function of measuring WBC, CRP, and PCT in detecting diabetic foot infection was not emphasized in the study above in terms of their effects on amputation owing to the different topics and patients included in the meta-analysis. But in this present study, the function of WBC, CRP, and PCT in detection of diabetic foot infection was more prominent. 

Several possible biological mechanisms can explain these findings. First, WBC count is the most basic marker of infection.25 When an infection occurs in a diabetic foot, the cause of the increased WBC counts may be increased production and release of WBCs in the bone marrow. Second, as a peptide produced in the liver, CRP is primarily stimulated by interleukin-6 and is used for complement binding and macrophage phagocytosis.27 Serious infection stimulates endothelial cells to produce interleukin-6, causing the liver to synthesize the acute phase proteins, including CRP. Third, PCT is a protein secreted by non-neuroendocrine parenchymal cells and is a PCT peptide.28 When infection occurs, target cells secrete PCT in response to lipopolysaccharide and other related factors, which results in the absence of essential hydrolases during post-transcription, leading to the observed increases in PCT level. One study notes that the most common pathogens in diabetic foot infection are gram-positive cocci, mainly Staphylococcus aureus and S epidermidis.29 Gram-negative bacteria are also common pathogens.29 Their effects will directly cause inflammatory reaction, leading to an increase in CRP level, WBC count, and PCT level. 

The function of WBC count in the detection of IDF was studied both because it is a common laboratory test indicator that can assist in detecting infection and other nonspecific inflammation30 and also because of the special innate immunity and acquired immunity of physiological and pathological functions.31 Additionally, a growing body of evidence shows that CRP, in addition to being an effective inflammatory marker, is also a direct mediator of the inflammatory response and innate immunity.32 Further studies on WBC count and CRP level could possibly help provide information for the prevention of diabetic foot infection by increasing the understanding of their immune function. Although the meta-analysis of PCT was unstable, the results show that PCT could play a role in detecting IDF. Two previous studies indicate that PCT plays a role in guiding the use of antibiotics.33,34 Thus, it is helpful to explore whether PCT can guide the application of antibiotics in the management of diabetic foot infection. In summary, WBC count, CRP level, and PCT level are useful laboratory assistant indexes for effective clinical detection of diabetic foot infection. Measurement of these markers is convenient and rapid, which is conducive to detecting early infection and supporting timely prevention measures.

Limitations

The present study does have limitations. First, the severity of diabetic foot infection varies.5 The study did not analyze the different severities of such infection because of the different approaches and patients of the included studies and the limited data. Second, the small sample size may lead to inadequate efficacy and publication bias. Third, although subgroup analysis was performed, considerable heterogeneity remained among the analysis groups, indicating other heterogeneity sources that could not be systematically evaluated. Further high-quality studies are needed to verify the findings of this study. 

Conclusions

In summary, there were significant differences in WBC count, CRP level, and PCT level between patients with IDF and patients with NIDF. These findings strengthen the evidence that diabetic foot infection is accompanied by abnormal levels of WBC, CRP, and PCT. These inflammatory markers can be effective laboratory indexes that play important roles in the detection of diabetic foot infection. Additionally, a thorough understanding of these mechanisms will help in the development of new strategies to prevent diabetic foot infection through monitoring WBC count, CRP level, and PCT level. 

Acknowledgments

Authors: Yu-Ting Wang, BS; Le-Xuan Zhang, BS; Yang Li, BS; Jun Zhao, BS; and Hong-Lin Chen, MD

Affiliation: School of Public Health, Nantong University, Nantong City, Jiangsu Province, People’s Republic of China

Corresponding Author: Hong-Lin Chen, School of Public Health, Nantong University, Nantong City, SeYuan Road 20#, Jiangsu Province 226001, People’s Republic of China; 206148587@qq.com 

Disclosure: The authors disclose no financial or other conflicts of interest.

References

1. Liu C, Shi WL, You JX, Li HY, Li L. An internet-based algorithm for diabetic foot infection during the COVID-19 pandemic. J Foot Ankle Res. 2020;13(1):37.

2. Tchero H, Kangambega P, Fluieraru S, Bekara F, Teot L. Management of infected diabetic wound: a scoping review of guidelines. F1000Res. 2019;8:737. doi:10.12688/f1000research.18978.1

3. Grigoropoulou P, Eleftheriadou I, Jude EB, Tentolouris N. Diabetic foot infections: an update in diagnosis and management. Curr Diab Rep. 2017;17(1):3. doi:10.1007/s11892-017-0831-1

4. Goh TC, Bajuri MY, S CN, Abdul Rashid AH, Baharuddin S, Zamri KS. Clinical and bacteriological profile of diabetic foot infections in a tertiary care. J Foot Ankle Res. 2020;13(1):36. doi:10.1186/s13047-020-00406-y

5. Bus SA, Van Netten JJ, Hinchliffe RJ, et al. Standards for the development and methodology of the 2019 International Working Group on the diabetic foot guidelines. Diabetes Metab Res Rev. 2020;36 Suppl 1:e3267.

6. Russell CD, Parajuli A, Gale HJ, et al. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: a systematic review and meta-analysis. J Infect. 2019;78(5):339–348. doi:10.1016/j.jinf.2019.02.006

7. Jonaidi Jafari N, Safaee Firouzabadi M, Izadi M, Safaee Firouzabadi MS, Saburi A. Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers? Int J Endocrinol Metab. 2014;12(1):e13376. doi:10.5812/ijem.13376

8. Korkmaz P, Koçak H, Onbaşı K, et al. The role of serum procalcitonin, interleukin-6, and fibrinogen levels in differential diagnosis of diabetic foot ulcer infection. J Diabetes Res. 2018;2018:7104352. doi:10.1155/2018/7104352

9. Massara M, De Caridi G, Serra R, et al. The role of procalcitonin as a marker of diabetic foot ulcer infection. Int Wound J. 2017;14(1):31–34. doi:10.1111/iwj.12536

10. van den Kieboom J, Bosch P, Plate JDJ, et al. Diagnostic accuracy of serum inflammatory markers in late fracture-related infection: a systematic review and meta-analysis. Bone Joint J. 2018;100-B(12):1542–1550. doi:10.1302/0301-620X.100B12.BJJ-2018-0586.R1

11. Mutluoğlu M, Uzun G, İpcioğlu OM, et al. Can procalcitonin predict bone infection in people with diabetes with infected foot ulcers? A pilot study. Diabetes Res Clin Pract. 2011;94(1):53–56. doi:10.1016/j.diabres.2011.05.023

12. Uzun G, Solmazgul E, Curuksulu H, et al. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J Exp Med. 2007;213(4):305–312. doi:10.1620/tjem.213.305

13. Karakas A, Arslan E, Cakmak T, Aydin I, Akgul EO, Demirbas S. Predictive value of soluble CD14, interleukin-6 and procalcitonin for lower extremity amputation in people with diabetes with foot ulcers: a pilot study. Pak J Med Sci. 2014;30(3):578–582. doi:10.12669/pjms.303.4575

14. Park JH, Suh DH, Kim HJ, Lee YI, Kwak IH, Choi GW. Role of procalcitonin in infected diabetic foot ulcer. Diabetes Res Clin Pract. 2017;128:51–57. doi:10.1016/j.diabres.2017.04.008

15. Lauri C, Glaudemans A, Campagna G, et al. Comparison of white blood cell scintigraphy, FDG PET/CT and MRI in suspected diabetic foot infection: results of a large retrospective multicenter study. J Clin Med. 2020;9(6). doi:10.3390/jcm9061645

16. Manja V, Lakshminrusimha S. Epidemiology and clinical research design, part 1: study types. Neoreviews. 2014;15(12):e558–e569. doi:10.1542/neo.15-12-e558

17. Cook DA, Reed DA. Appraising the quality of medical education research methods: the Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education. Acad Med. 2015;90(8):1067–1076. doi:10.1097/ACM.0000000000000786

18. Wang D, Mou ZY, Zhai JX, Zong HX, Zhao XD. Application of Stata software to test heterogeneity in meta-analysis method. Article in Chinese. Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29(7):726–729.

19. Huedo-Medina TB, Sánchez-Meca J, Marín- MartínezF, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206. doi:10.1037/1082-989X.11.2.193

20. Aslan S, Demirdal T, Erbak H, Aslan C. The role of soluble urokinase plasminogen activator receptor (suPAR) in the diagnostics of diabetic foot infection. Infect Dis (Lond). 2020;52(2):107–113. doi:10.1080/23744235.2019.1688387

21. Ingram JR, Cawley S, Coulman E, et al. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study). Diabet Med. 2018;35(2):255–261. doi:10.1111/dme.13431

22. Karmaker M, Sanyal SK, Sultana M, Hossain MA. Association of bacteria in diabetic and non-diabetic foot infection - an investigation in patients from Bangladesh. J Infect Public Health. 2016;9(3): 267–277. doi:10.1016/j.jiph.2015.10.011

23. Ong E, Farran S, Salloum M, et al. Does everything that’s counted count? Value of inflammatory markers for following therapy and predicting outcome in diabetic foot infection. Int J Low Extrem Wounds. 2017;16(2):104–107. doi:10.1177/1534734617700539

24. Umapathy D, Dornadula S, Rajagopalan A, et al. Potential of circulatory procalcitonin as a biomarker reflecting inflammation among South Indian diabetic foot ulcers. J Vasc Surg. 2018;67(4):1283–1291.e2. doi:10.1016/j.jvs.2017.02.060

25. Zakariah NA, Bajuri MY, Hassan R, et al. Is procalcitonin more superior to hs-CRP in the diagnosis of infection in diabetic foot ulcer? Malays J Pathol. 2020;42(1):77–84.

26. Sen P, Demirdal T, Emir B. Meta-analysis of risk factors for amputation in diabetic foot infections. Diabetes Metab Res Rev. 2019;35(7):e3165. doi:10.1002/dmrr.3165

27. Li S, Renick P, Senkowsky J, Nair A, Tang L. Diagnostics for wound infections. Adv Wound Care (New Rochelle). 2021;10(6):317–327. doi:10.1089/wound.2019.1103

28. Liu LN, Wang P, Guan SY, et al. Comparison of plasma/serum levels of procalcitonin between infection and febrile disease flare in patients with systemic lupus erythematosus: a meta-analysis. Rheumatol Int. 2017;37(12):1991–1998. doi:10.1007/s00296-017-3827-x

29. Mavrogenis AF, Megaloikonomos PD, Antoniadou T. et al. Current concepts for the evaluation and management of diabetic foot ulcers. EFORT Open Rev. 2018;3(9):513–525. doi:10.1302/2058-5241.3.180010

30. Luo J, Chen C, Li Q. White blood cell counting at point-of-care testing: a review. Electrophoresis. 2020;41(16–17):1450–1468. doi:10.1002/elps.202000029

31. Tajuddin SM, Schick UM, Eicher JD, et al. Large-Scale Exome-Wide Association analysis identifies loci for white blood cell traits and pleiotropy with immune-mediated diseases. Am J Hum Genet. 2016;99(1):22–39. doi:10.1016/j.ajhg.2016.05.003

32. McFadyen JD, Kiefer J, Braig D, et al. Dissociation of c-reactive protein localizes and amplifies inflammation: evidence for a direct biological role of c-reactive protein and its conformational changes. Front Immunol. 2018;9:1351. doi:10.3389/fimmu.2018.01351

33. Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191. doi:10.1186/s13054-018-2125-7

34. Lam SW, Bauer SR, Fowler R, Duggal A. Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies. Crit Care Med. 2018;46(5):684–690. doi:10.1097/CCM.0000000000002953

Advertisement

Advertisement

Advertisement